FDA Approves Afrezza for Pediatric Use, Fulfilling Final Postmarketing Requirement
MNKD sits 57% above its 52-week low of $2.23.
Summary
MannKind announced FDA approval for its Afrezza insulin inhalation powder for pediatric use, which also fulfills the final postmarketing requirement for the drug.
Key Events · Product Development and Regulatory · MNKD
-
FDA Approval for Pediatric Use
The U.S. Food and Drug Administration (FDA) approved Afrezza (insulin human) Inhalation Powder for use in children and adolescents aged 6 and older living with type 1 and type 2 diabetes.
-
Expanded Market Opportunity
This approval opens a new market segment, as more than 350,000 children and adolescents in the United States are living with diabetes, the majority requiring lifelong insulin therapy.
-
Final Postmarketing Requirement Met
The supplemental biologics license application for the pediatric indication has fulfilled the last remaining postmarketing requirement for Afrezza, removing a significant regulatory overhang.
Analysis · MNKD · Life Sciences
This FDA approval significantly expands the addressable market for Afrezza to include children and adolescents aged 6 and older with type 1 and type 2 diabetes, a population exceeding 350,000. Crucially, this approval also satisfies the last remaining postmarketing requirement for Afrezza, removing a significant regulatory burden and associated costs for MannKind.
At the time of this filing, MNKD was trading at $3.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $2.23 to $6.51. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.